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Abstract The aims of this study were to determine whether
placebo treatment in randomised controlled trials (RCTs) is
effective for fibromyalgia and to identify possible determinants
of the magnitude of any such placebo effect. A systematic lit-
erature search was undertaken for RCTs in people with fibro-
myalgia that included a placebo and/or a no-treatment (obser-
vation only or waiting list) control group. Placebo effect size
(ES) for pain and other outcomes wasmeasured as the improve-
ment of each outcome from baseline divided by the standard
deviation of the change from baseline. This effect was com-
pared with changes in the no-treatment control groups. Meta-
analysis was undertaken to combine data from different studies.
Subgroup analysis was conducted to identify possible determi-
nants of the placebo ES. A total of 3912 studies were identified
from the literature search. After scrutiny, 229 trials met the
inclusion criteria. Participants who received placebo in the
RCTs experienced significantly better improvements in pain,
fatigue, sleep quality, physical function, and other main out-
comes than those receiving no treatment. The ES of placebo
for pain relief was clinically moderate (0.53, 95%CI 0.48 to
0.57). The ES increased with increasing strength of the active
treatment, increasing participant age and higher baseline pain
severity, but decreased in RCTS with more women and with
longer duration of fibromyalgia. In addition, placebo treatment
in RCTs is effective in fibromyalgia. A number of factors (ex-
pected strength of treatment, age, gender, disease duration)
appear to influence the magnitude of the placebo effect in this
condition.
Keywords Fibromyalgia .Meta-analysis . Pain
management . Placebo effect . Rheumatic diseases .
Systematic reviews andmethodology
Introduction
Fibromyalgia (FM) is a common chronic multiple regional pain
syndrome, affecting approximately 2% of people in the general
population [1]. The condition is eight times more common in
women than in men [2] and increases with age [3]. The main
symptoms of fibromyalgia include widespread pain, fatigue,
non-restorative sleep, and cognitive impairment [4].
Treatments for fibromyalgia include non-pharmacologic thera-
pies such as patient education, aerobic exercise, acupuncture
and cognitive behavioural therapy, and pharmacologic thera-
pies such as analgesics and anti-depressants. Placebo has been
proved to be effective in many conditions such as depression
[5] chronic fatigue syndrome [6], Parkinson’s disease [7], irri-
table bowel syndrome [8] and osteoarthritis (OA) [9]. The mag-
nitude of placebo effect is known to be influenced by a number
of factors [10, 11]. In OA, placebo appears to be more effective
in subjective outcomes such as self-reported pain, function,
stiffness and physician global assessment [12]. A single system-
atic review in 2011 attempted to identify the magnitude and
patient-specific predictors of placebo response in FM, and the
year of study initiation, pain baseline, and effect size in active
drug groups were found to be associated with the placebo re-
sponse [13]. However, whether a placebo is effective in FM and
what the determinants are of any such effect remain unknown.
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Methods
Literature search
A systematic literature search was carried out up until October
2015, using Medline (1950–present), Web of Science (1960–
present), EMBASE (1980–present), Cumulative Index to
Nursing and Allied Health Literature (CINAHL) (1982–pres-
ent), and Allied and Complementary Medicine (1985–present).
The search strategies included: [1] search for FM; [2] search for
randomised controlled trials (RCTs). Other terms that were
used for FM and RCTs such as chronic widespread pain, fibro-
sitis, double blind method, single blind method and compara-
tive study were also included (Appendix 1). There were no
language restrictions for this search. Citations were imported
into Endnote X7 and duplications were removed. Titles and
abstracts were read to judge whether the studies met the inclu-
sion criteria. Full papers were obtained for further scrutiny of
relevant studies according to the inclusion/exclusion criteria.
Inclusion and exclusion criteria
Only RCTs with placebo controlled groups and/or no-treatment
control groups in FM or chronic widespread pain were included.
Trials that only compared two active treatments or which studied
several chronic pain conditions without clear definition or sepa-
ration of FM/chronic widespread pain were excluded. Trials that
did not have any clinical outcomes were also excluded.
Data extraction
A data extraction form was developed to collect data from
each of the included studies. The following information was
extracted from each study: study design (parallel or cross-
over), study setting (hospital or community), funding body
(industry, charity or academic), sample size (treatment group
and control group), mean age of participants and standard
deviation (SD), percentage of women participants, and out-
come measures at both baseline and endpoint.
Outcome measures
Primary outcomes of the study included pain, fatigue, sleep
quality and physical function. The outcomes were decided
before the literature search in order to get the relevant studies.
After reviewing all retrieved studies, the visual analogue scale
(VAS) was found commonly used to measure pain reduction.
In fatigue measurement, the Multidimensional Fatigue
Inventory (MFI) was the most commonly used tool. MFI is
a 20-item self-report instrument designed to measure fatigue
that covers the following dimensions: general fatigue, physi-
cal fatigue, mental fatigue, reduced motivation and reduced
activity [14]. Pain, fatigue and sleep quality measured by VAS
were taken if reported. Other scales such as the Likert scale
and categorical scale were used when VAS was not available.
Standardised mean difference was calculated in the meta-
analysis to avoid heterogeneity that was caused by the usage
of different measurement tools for the same outcome.
Secondary outcomes included quality of life (QOL), par-
ticipant and observer assessment of overall wellbeing, and
others. The Fibromyalgia Impact Questionnaire (FIQ) and
SF36 were normally used as disease-specific and generic
QOL instruments respectively in FM. Other QOL measure-
ments were also included.
Quality assessment and data validation
Details of randomisation (yes/no/unknown), allocation con-
cealment (adequate/inadequate/unknown), blinding to partici-
pants, care providers and assessors (yes/no/unknown), dropout
(%), intention-to-treat analysis (yes/no/unknown), recruitment
setting (community/hospital/unknown) and funding body (in-
dustry/non-industry/unknown) were assessed for each trial.
The data were first extracted independently by the main
reviewer (X.C). Subsequently, a second reviewer (K.Z.) ran-
domly selected 10% of the studies and extracted the data in-
dependently. Agreement was examined between the two data
extractions. If a disagreement of more than 5%was found, the
full data extraction was undertaken by the second reviewer.
Disagreement was discussed and consensus was achieved
with other reviewers (M.D. and W.Z.).
Statistical analysis
Effect size (ES), that is the standardised mean difference
(SMD), was calculated for each outcome measure. The ES
standardises the difference using the pooled within group SD
between baseline and endpoint. It therefore normalises themea-
sures across studies which permits the combined analysis.
However, unlike the natural measure of the outcome such as
pain on a visual analogue scale (VAS–where pain severity is
scored from 0 to 100 mm), ES measures the size of effect in the
unit of SD. According to Cohen’s definition, an ES of 0.2 (i.e.
20% of SD) suggests a small effect, an ES of 0.5 (i.e. 50% of
SD) indicates a moderate effect, and an ES of 0.8 (80% of SD)
or more is a large effect [15]. Hedges (1982) method was used
to calculate ES and its 95% confidence intervals (CI) to further
adjust for sample size [16]. ES from baseline to the endpoint
was calculated for each study arm. Comparison was made be-
tween placebo and no-treatment groups to establish the placebo
effect on the basis of no overlapping between the two 95%CIs.
A funnel plot (Appendix 2) was used to examine the possibility
of publication bias in each analysis. The Egger’s test was used
for asymmetry of the funnel plot [17]. I2 (a measure for incon-
sistency among studies ranging from 0 to 100%) was used to
measure heterogeneity [18]. The larger the I2, the greater the
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inconsistency or heterogeneity of study result. The Q test was
applied to determine whether any heterogeneity was statistical-
ly significant [19]. Subgroup analysis was undertaken accord-
ing to treatment and trial characteristics.
Results
Characteristics of the trials
In total, 3912 citations were retrieved from all databases. After
removing duplicates, 3706 citations remained. After reading
abstracts, 286 studies were found relevant. Full studies were
retrieved and examined. Subsequently, 229 of these met the
inclusion criteria. In order to perform meta-analysis, both the
means and SDs of each outcome measure are needed. Trials
that failed to provide suitable data were not included in the
quantitative meta-analysis. A total of 105 eligible trials could
not be included in the analysis because of the lack of suitable
data. Finally, 124 trials remained for meta-analysis (Fig. 1).
A total of 15,633 participants were included in the 124
trials. More trials used placebo as a comparator than a no-
treatment control (73 vs 51). The demographic characteristics
(mean age, percentage of women, etc.) of the participants in
placebo groups did not different from that of the no-treatment
groups. The majority of the trials (70%) reported pain as an
outcome. Other commonly reported outcomes were fatigue,
sleep quality and physical function (Table 1).
The funnel plot of ESs for pain reduction from baseline in
either placebo or no-treatment groups showed an asymmetric
distribution (Egger’s p = 0.04), i.e. trials with smaller ES with
placebo or no-treatment control groups were more likely to be
published.
Efficacy of placebo versus no treatment
Compared with the ESs of no-treatment (observation only)
groups, placebo was statistically superior to no treatment in
all outcomes of FM, apart from Beck’s Depression Index
(BDI) and number of tender sites (Fig. 2). The magnitude of
placebo effect was clinically moderate in pain reduction,
(ES = 0.52, 95%CI 0.48 to 0.57). The ES varied from study
to study. Heterogeneity in these studies was high (I2 = 74.2%,
P < 0.0001). Similar results were observed in other outcomes.
The results were summarised in Table 2.
Determinants of the placebo effect
In the subgroup analysis, the placebo ES increased with the
mean age of participants in a trial. The placebo ES was 0.42
(95%CI 0.16 to 0.68) for people under 40 years, 0.51 (95%CI
0.47 to 0.56) for people aged 40–50 years, and 0.68 (95%CI
0.57 to 0.79) for those aged over 50 years, respectively. With
respect to gender, the more women included in a trial, the less
effective was placebo. Trials with <80%women had a placebo
ES of 0.65 (95%CI 0.32 to 0.98), whereas trials with 100%
women had a placebo ES of 0.21 (95%CI 0.02 to 0.39).
Studies of participants with a shorter mean duration of FM
(3–7 years) tended to have a larger placebo ES (0.59, 95%CI
0.51 to 0.76) than those with longer mean duration of FM
(over 13 years) (0.26, 95%CI -0.09 to 0.60). Baseline pain
severity also appeared to influence placebo ES. Groups with
the lowest mean baseline pain severity (<60%) had the
Total citaons 3912 
3706 
Eligible abstracts 286 
Eligible studies  
229 
57 studies were excluded because of  
No clinical outcome 9  
Acve controlled 40 
No control group 8 
Duplicates 206 
Studies for 
meta-analysis 124 
105 studies were excluded because of
insuﬃcient data reported
Fig. 1 Flowchart of literature
search
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smallest placebo effect (ES 0.22, 95%CI 0.06 to 0.42) and
there was a tendency for increasing placebo effect with higher
baseline pain severity (Table 3).
In addition, the placebo ES correlated significantly with the
treatment ES (r = 0.70, p < 0.0001) (Fig. 3), i.e. placebo effect
increased with the strength of active treatment.
Other potential determinants of the placebo effect were
examined, including study setting (community, hospital),
and blinding. However, due to the limited resources, no clear
tendency was found.
Discussion
The literature search identified over 200 placebo-
controlled trials examining a wide range of different treat-
ments for FM including drugs, physical interventions such
as exercise and balneotherapy, psychological treatments
such as CBT, and complementary therapies such as home-
opathy and acupuncture. Some trials used placebo as the
control while others used a no-treatment (observation on-
ly) group as a comparator. This provided an excellent
opportunity to investigate the placebo effect and its deter-
minants in FM. The study yielded three key findings.
Firstly, participants receiving placebo treatment in RCTs
obtain significant improvements in all the main outcome
measures such as pain, fatigue, sleep quality, function and
overall wellbeing. Secondly, these effects are superior to
any changes observed in control groups who received no
treatment. Thirdly, the magnitude of the placebo effect
increases with the effect size of the active treatment, and
is greater in people with more severe symptoms, in those
with shorter duration of FM, in men more than women
and in older compared to younger people with FM.
Table 1 Demographic
Characteristics of Included Trials Total Control
Placebo Untreated
No. of trials 124 73 51
No. of participants 15,633 12,041 3592
Mean age, range (year) 49.2 (29.4 to 59.0) 49.0 (29.4 to 59.0) 49.4 (40.8 to 58.5)
Women (0–100) % 95.4 (63.7 to 100) 94 (63.7 to 100) 100 (74 to 100)
Percentage of trials reporting
Pain 70% 72%
Fatigue 41% 32%
Sleep disturbance 25% 26%
Physical function 19% 30%
FIQ total score 45% 62%
BDI total score 12% 17%
No. of tender sites 32% 30%
FIQ Fibromyalgia Impact Questionnaire, BDI Beck’s Depression Index
Fig. 2 Comparison of placebo
group and the untreated group
FIQ Fibromyalgia Impact
Questionnaire; BDI Beck’s
Depression Index
Clin Rheumatol
The debate concerning whether placebo treatment works
for medical conditions has continued since Beecher’s land-
mark paper in 1955 entitled “The powerful placebo” [20].
Many studies suggest that the placebo response in RCTs
highlighted by Beecher may be explained by spontaneous
changes such as the natural variation of disease and regression
to the mean [21–24]. Therefore, the comparison between pla-
cebo and no-treatment observational groups is essential to
confirm whether placebo is effective or not [25]. We under-
took such a comparison and found that receiving a placebo is
significantly better than receiving no treatment for pain and
other patient-centred outcomes of FM such as sleep, fatigue,
function and overall quality of life. This finding is in line with
a systematic review of RCTs of treatments in OAwhich found
placebo treatment to be clinically effective for pain (ES, 0.51,
95%CI 0.46 to 0.55) and other outcomes of OA [10].
The observation that placebo ES goes up with the strength of
active treatment is consistent with the recognised importance of
patient expectancy for treatment in determining the magnitude
of placebo effect [26, 27]. A positive association between se-
verity of baseline pain and magnitude of placebo effect, as
found in our study, has also been reported in OA RCTs [12].
This also accords with the observation in Parkinson’s disease
that patients with greater baseline functional impairment are
more likely to have a higher placebo effect [28]. The lower
placebo ES observed in trials of participants with longer mean
duration of FM accords with the observation that early interven-
tion in FM is more likely to give a good outcome [28]. This
implies that the longer a person has FM, the more entrenched
the condition becomes, the lower the patient expectancy and the
harder it is to improve outcomes by either active treatment or
placebo and by other factors that influence contextual response.
Gender has been suggested previously to influence placebo
response [29] with men appearing to be better placebo re-
sponders in some studies [30, 31]. The finding of the present
study is in agreement with this. Pain physiology differs between
men and women, and it is possible that ability to influence
descending inhibition of pain through expectancy differs consti-
tutionally between men and women [32, 33]. This is particularly
pertinent in that women are more likely to have FM and other
chronic pain than men, and the management of these types of
pain is more challenging in women [34, 35]. One possible ex-
planation is that women perceive disease differently from men
[36]. Women may perceive an excess of symptoms compared
with men, because of greater attention and increased attribution
of bodily sensations to physical illness [37]. Another reason is
Table 2 Placebo Effect by Outcome Measures in Fibromyalgia
Outcome No. of trials No. of participants Pooled effect size (95%CI) Publication bias (Egger) Heterogeneity (I2)
Pain reduction 51 4472 0.52 (0.48, 0.57) −0.95, p = 0.04 74%, p < 0.0001
Fatigue 30 3465 0.31 (0.26, 0.36) −0.30, p = 0.45 25%, P = 0.1078
Physical function 14 2435 0.27 (0.22, 0.33) −1.47, p = 0.05 46.7%, p = 0.0276
Sleep quality 18 1048 0.41 (0.32, 0.49) −0.90, p = 0.07 0%, p = 0.5195
FIQ total score 33 3897 0.47 (0.43, 0.49) 0.19, p = 0.76 64.3%, p < 0.0001
BDI total score 9 1504 0.21 (0.14, 0.29) 0.06, p = 0.95 51.7%, p = 0.0351
No. of hyperalgesic tender sites 23 1120 0.30 (0.21, 0.38) 1.58, p = 0.24 84.4%, p < 0.001
Table 3 Subgroup analysis for possible determinants
No. of trials No. of patients ES (95%CI) Heterogeneity (I2) PPublication bias
Mean age (years)
<=40 5 115 0.42 (0.16, 0.68) 66.1%, p = 0.02 0.60
>40, <=50 30 3474 0.50 (0.45, 0.55) 67.3%, p < 0.0001 0.81
>50 12 711 0.62 (0.53, 0.70) 82.7%, p < 0.0001 0.03
Women%
<80% 4 77 0.65 (0.32, 0.98) 52.6%, p = 0.09 0.86
>80%, <90% 7 500 0.48 (0.35, 0.61) 64%, p = 0.01 0.50
>90%,<100% 22 3342 0.56 (0.52, 0.61) 82.4%, p < 0.0001 0.78
100% 9 277 0.21 (0.02, 0.39) 42.2%, p = 0.09 0.60
Mean disease duration
3–7 years 13 1237 0.59 (0.51, 0.67) 76.3%, p < 0.0001 0.30
8–12 years 9 1208 0.57 (0.49, 0.65) 88%, p < 0.0001 0.46
13 years 2 65 0.26 (−0.09, 0.60) N/A* N/A*
Baseline pain severity (%)
<60 8 195 0.22 (0.06, 0.42) 32.26, p = 0.1657 0.98
60–70 23 3025 0.54 (0.49, 0.59) 75.3, p < 0.0001 0.43
>70 15 1147 0.56 (0.48, 0.65) 79.9%, p < 0.0001 0.40
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that men may be better responders to treatments in general [38].
For example, in patients with Achilles tendinopathy, eccentric
training results in significantly greater pain reduction in men
than women [38]. Men also respond better than women to
non-painful conditions, such as pulmonary arterial hypertension
[39] and growth hormone deficiency [40]. The role of personal-
ity trait might also cause a gender difference in placebo re-
sponse. High dispositional optimism and low state anxiety have
been found to be significant predictors of placebo response and
they associate with male gender [41].
A greater placebo response in older people has been
reported in previous studies. According to Alexopoulos,
more than half of elderly people with depression show at
least 25% improvement from taking placebo [42]. In trials
in Parkinson’s disease older individuals also show a sig-
nificantly greater response to placebo [28]. Older people
with FM also responded better to placebo in the current
review. This could be explained by the fact that people of
different ages have difference illness perceptions and ex-
pectancy. Although the prevalence of FM goes up with
age, older people report less severe symptoms [43].
They may also be more likely to regard pain as part of
the ageing process, to have less anxiety associated with
this, and to cope with it better [43]. Whether this age-
related placebo effect in FM is related to experience, so-
cial ability and other contextual factors deserves further
study.
There are a number of caveats to this study. Firstly, the
included trials may not cover all eligible trials in FM,
especially those that are unpublished. Furthermore, many
included trials did not present their result in numerical
data and could not be used for the meta-analysis.
Secondly, inclusion of many disparate treatments and their
placebo in this review resulted in high heterogeneity for
the placebo effect. Although we carefully considered the
reasons for marked heterogeneity and undertook a number
of subgroup analyses, the heterogeneity still remained for
some subgroups and a random effects model had to be
used to pool the data. Thirdly, the determinants were ex-
amined by individual factors in subgroup analysis.
Therefore, only a brief tendency can be determined.
Further study of the determinants for the placebo effect
is warranted. Furthermore, the influence of gender and
age on the placebo effect would best be studied using
individual participant data rather than a meta-analysis of
trials where only the gender proportion and mean ages are
available in each trial.
In conclusion, placebo treatment appears to be clinically
effective in FM in reducing pain and fatigue and improving
non-restorative sleep and overall quality of life. Its analgesic
effect is clinically significant. Greater placebo effect may be
observed in men, in older people and in those with more
severe pain, whereas a lower placebo effect is seen in those
with longer established FM. Further studies using individual
participant data are required to better identify the individual
predictors of placebo effect size.
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Appendix 1. Searching strategy
Medline OVID 1948–present
1. exp Meta-Analysis/
2. systematic review.mp.
3. quantitative review.mp.
4. quantitative overview.mp.
5. statistical pool.mp.
6. 1 or 2 or 3 or 4 or 5
7. exp Randomized Controlled Trial/
8. exp Clinical Trial/
9. exp Double-Blind Method/
10. exp Single-Blind Method/
11. Comparative Study/
12. 7 or 8 or 9 or 10 or 11
13. exp Fibromyalgia/
14. fibromyalgia syndrome.mp.
15. Chronic widespread pain.mp.
16. Fibrositis.mp. or Fibromyalgia/
17. 13 or 14 or 15 or 16
18. 12 and 17
19. 6 and 17
20. 18 or 19
Appendix 2. Funnel plots for different outcomes
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